Form 4: Cytosorbents Director Alan D. Sobel Exercises Rights, Acquires Shares and Warrants

Alan D. Sobel, a director at Cytosorbents Corp, exercised subscription rights to acquire shares and warrants, increasing his holdings in the company.

Summary

• Alan D. Sobel, a director of Cytosorbents Corp, exercised subscription rights on January 17, 2025, as part of a rights offering.
• He acquired 21,950 shares of common stock, along with Series A and Series B warrants, at a price of $1.00 per unit, totaling $21,950.
• The Series A warrants have an exercise price based on 90% of the 5-day volume weighted average price of the common stock prior to their expiration, with a floor of $1.00 and a ceiling of $2.00.
• The Series B warrants have a similar exercise price calculation, with a floor of $2.00 and a ceiling of $4.00.
• The Series A warrants expire 45 calendar days after the closing date of the rights offering, which was January 10, 2025.
• The Series B warrants expire 90 calendar days after the closing date.
• Sobel also holds 123,807 shares of common stock, including restricted stock units that vest upon a change of control, and 2,000 shares held indirectly through the Bernard Sobel Revocable Trust.

Sentiment

Score: 7

Explanation: The document reflects a positive action by a director, indicating confidence in the company. The transaction is part of a planned capital raise, which is generally viewed positively.

Positives

• The director's participation in the rights offering demonstrates confidence in the company's future.
• The exercise of rights increases the director's stake in the company, aligning his interests with those of other shareholders.

Risks

• The value of the warrants is dependent on the future performance of the company's stock price.
• The exercise price of the warrants is variable and could be higher than the current market price.

Future Outlook

The value of the warrants will depend on the future performance of the company's stock price. The exercise of the warrants could lead to further dilution of the company's stock.

Industry Context

This type of transaction is common for companies seeking to raise capital and incentivize key stakeholders. Rights offerings allow existing shareholders to maintain their ownership percentage.

Comparison to Industry Standards

• Rights offerings are a standard method for companies to raise capital, particularly in the biotech and pharmaceutical sectors where Cytosorbents operates.
• The terms of the warrants, with variable exercise prices based on the stock's performance, are also common in such offerings.
• Comparable companies often use similar structures to incentivize participation in capital raises.

Stakeholder Impact

• Shareholders may view the director's participation in the rights offering as a positive sign.
• The exercise of warrants could lead to dilution of existing shares.

Next Steps

• The director may exercise the warrants in the future, depending on the stock price.
• The company will likely continue to monitor the stock price and the exercise of warrants.

Key Dates

Keywords

Cytosorbents, Alan D. Sobel, rights offering, warrants, common stock, beneficial ownership, director, subscription rights